23andMe Headquarters
23andMe Headquarters [JasonDoiy/Getty Images]

Anne Wojcicki, co-founder and former CEO of direct-to-consumer genetic testing company 23andMe, has succeeded in a bid to buy almost all the assets of the bankrupt company through a nonprofit set up by Wojcicki in May this year called TTAM.

TTAM has undeclared backers in industry, and according to its website “is a nonprofit medical research organization dedicated to helping scientists and non-scientists join together to unravel the mysteries of DNA.”

The bid of $305 million includes 23andMe’s core genetic testing and telehealth businesses and surpassed a previous bid from Regeneron Pharmaceuticals of $256 million made last month.

For the acquisition to go through, the U.S. Bankruptcy Court for the Eastern District of Missouri needs to approve the sale and a hearing for this decision is scheduled for tomorrow.

23andMe filed for chapter 11 bankruptcy in March this year with Wojcicki stepping down with immediate effect after the filing.

The company went public in 2021 by merging with VG Acquisitions, a special-purpose acquisitions company formed by Richard Branson’s Virgin Group. It had a market cap of more than $6 billion at the time, but its value has dropped significantly in recent years to under $50 million prior to this week’s bankruptcy protection filing.

One reason for the drop in value was a large data breach in 2023 that led to almost seven million of 23andMe’s customers’ data being stolen by hackers. This led to a drop in customer confidence in the firm and a lawsuit, which resulted in a $30 million payout in September 2024.

Wojcicki made an offer earlier this year to take the company private for 41 cents per share, but this offer was rejected by a special committee of independent directors prior to the start of bankruptcy proceedings.

Wojcicki complained to the bankruptcy court that Regeneron’s bid for the company had been accepted too quickly in May without a chance for further bids, which prompted a new round of bidding that ultimately led to TTAM winning the round.

As part of the announcement about the bid, TTAM has assured previous customers of 23andMe that customer data will be protected, and privacy safeguards will remain in place.

“I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe to help people access, understand and benefit from the human genome. We believe it is critical that individuals are empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish,” said Wojcicki.

“The 23andMe community of consented individuals will also have the opportunity to be part of making novel genetic discoveries that improve our knowledge of DNA—the code of life— and the health and wellness of everyone. I remain committed to the 23andMe community and driving forward this mission.”

Also of Interest